Peptides for appetite control

Peptides for appetite control

DNF-10® is a hydrolysate fraction from Saccharomyces cerevisiae which acts on the gut-brain mediators of satiety, to lower calorie intake and reduce body fat mass. Benefits demonstrated after the first weeks. Supported with 4 published clinical trials. 500 mg/day.

download brochure

DNF-10® - Key features

  • Patented ingredient

  • Demonstrated mechanism of action: gut-brain axis moderation of the appetite

  • Significant reduction of calorie intake after first weeks of supplementation

  • Significant weight loss after the first month

  • The weight lost is from fat mass

  • Abdominal fat and waist circumference decrease significantly

Science supporting DNF-10®

More than 10 years of research have been conducted to support the mechanism of action and clinical benefits of DNF-10® on body composition. The mechanism of action of DNF-10® on the mediator of satiety has been studied in vivo in animal models. The reduction of food intake and improvement of body composition have been confirmed with interventional human clinical trials.

More than 10 articles supporting the mechanism of action and health benefits of DNF-10® have been published.

Process & characterisation

DNF-10® is an active fraction produced by the protein hydrolysis of Saccharomyces cerevisiae, a yeast species used for thousands of years in baking, fermented food and beverage manufacturing processes. 

The manufacturing of DNF-10® involves enzymatic proteolysis and the use of ultrafiltration to select peptides with a molecular weight <10 kDa. The material is then spray-dried to obtain a dried powder. 

Active compounds:
  Patented yeast protein hydrolysate from Saccharomyces cerevisiae
  Strain NBRC (ex. IFO) 2346
  Peptide size: <10 kDa

Composition: Saccharomyces cerevisiae extract.

Recommended daily dosage: from 500 mg

Mechanism of action

DNF-10® acts on the gut-brain axis by regulating the hormones of appetite. 

Mechanistic studies demonstrated that DNF-10 is efficient to decreasing appetite signalling by modulating the central and peripheral mediators.  

DNF-10 mechanism of action

_______________________________________

 

  • In the stomach, the hunger hormone, ghrelin, significantly reduced with DNF-10.

  • In the small intestine, DNF-10 significantly enhances cholecystokinin (CCK) secretion, slowing gastric emptying and promoting satiety and improves the release of the Gastric Inhibitory Peptide (GIP), promoting insulin secretion. 

 

  • In the colon, DNF-10 modulates the peptide YY (PYY) and GLP-1 secretion, with GLP-1 levels increasing several-fold, reinforcing its role in inhibiting gastric mobility and prolonging satiety. 

  • In the hypothalamus, the release of the neuropeptide Y is activated. 

Complementary investigation demonstrated that DNF-10 not only stimulates enterohormones but also interacts with dipeptidyl peptidase-4 (DPP-4), an  enzyme responsible for GLP-1 degradation.  

Thanks to the inhibition of  DPP-4 activity by DNF-10, GLP-1 has better chance to remain effective longer in the metabolism. The combined effect—enhanced GLP-1 release and reduced degradation—amplifies appetite regulation, contributing to decreased energy intake as demonstrated in clinical studies.   

Clinically supported benefits

Double-blind, randomised, placebo-controlled clinical studies.

YEAR & DURATION 2014
10 weeks

2017
8 weeks
POPULATIONS

54 subjects
Men and women
BMI> 25 kg/m2
Age: 20-50 years old

 30 subjects
Women
BMI> 25 kg/m2
Age: 20-60 years old
PROTOCOLS

Abdominal fat distribution
Computed tomography

No specific exercise and diet patterns
Food record (Can-Pro)

Body composition
Impedance bioelectrical scale

No specific exercise and diet patterns
Food record (Can-Pro)
INTAKES SACHETS
2 x 500 mg/day		 CAPSULES
2 x 250 mg/day

Satiety enhancer

  • Subjects taking DNF-10® supplements decrease their caloric intake significantly after the first weeks of supplementation.
  • After 2 months, the daily caloric intake drops by 600 kcal.
  • All 3 groups of macronutrients are significantly impacted: subjects reduce the number of calories from lipids, proteins, and carbohydrates.
  • After a few weeks of consuming DNF-10®, subjects have a reduced appetite for sweet foods. 

Body weight loss

Weight loss is significant after one month of supplementation with DNF-10®. Moreover, 100% of the weight lost is from fat mass, leading to a 6% reduction in the fat mass ratio.

Abdominal fat reduction

The change in  body composition is confirmed by computed tomography. The subjects’ total abdominal fat mass is significantly reduced by 5% with DNF-10®. Waist circumference is reduced by 5 cm after supplementation. 

DNF-10® is safe

No adverse event linked to DNF-10® supplementation has been recorded.

Regulatory & Applications

GRAS self-affirmed with FDA notification GRN1033

Non-GMO project certified, Halal, gluten-free, suitable for vegetarians

Stability validated after heat treatment at 160°C/320°F for 30 min

References

CLINICAL TRIALS
Hong K. et al.; Progr. Nutr., 2015, 17:3:262-264
Jung E. et al.; Phytother. Res., 2009, 3(5):619-23
Jung E. et al.; Nutrition; 2014, 30:25-32
Jung E. et al.; Prev. Nutr. Food Sci.; 2017, 22(1):45-49

MECHANISTIC STUDIES
Park Y. et al.; Food Chemistry, 2013
Jung E.Y. et al., Ann. Nutr. Metab. 2012; 61(2):89-94
Jung E.Y. et al.; Journal of Health Science, 2011; 57(6), 532-539

This website is intended to provide information about Fytexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.